WCFF Events – ScanScor

ScanScor WCFF Events

Total Events 6142

Fish Alarms 2546

Chart Now 3025

UP / DOWN / UNCERTAIN 866 / 1566 / 3710

Max Repricing 99%

Max Fade Risk 99%

Created	Ticker	Direction	Alarm	Type	Risk	Headline	Reason
2026-09-22 01:57:42 Story: 2026-09-21 21:56:16	PDSB ID 6142	DOWN Up 18% / Down 72%	Fish: YES Chart: YES MEDIUM	STRAY_WILDCAT_DOWN FINANCING ScanScor Filing Bot	Reprice: 67% Fade: 79% Thesis Break: 64% Today: 0.68 - 0.92	PDSB SEC filing points to financing activity Parse: PARSED	13D confirms large PIPE and warrant overhang already announced, reinforcing dilution pressure despite strategic investor optics. Input: ADEQUATE - Fresh filing is usable, but much of the financing was previously disclosed, reducing novelty.
2026-09-21 23:39:43 Story: 2026-09-21 19:37:00	AVXL ID 6141	DOWN Up 8% / Down 58%	Fish: NO Chart: YES MEDIUM	WATCH_CHART OTHER PRNewswire RSS	Reprice: 34% Fade: 82% Thesis Break: 28% Today: 2.28 - 2.46	Rosen Law Firm Encourages Anavex Life Sciences Corp. Investors to Inquire About Securities Class Action Investigation - AVXL Parse: PARSED	Law firm investigation is usually derivative, but it can add modest near-term pressure to an already weak, credibility-damaged biotech chart. Input: ADEQUATE - Freshness and context are sufficient; this is not a core business catalyst and likely has limited standalone repricing power.
2026-09-21 23:35:54 Story: 2026-09-21 19:34:00	TYGO ID 6140	DOWN Up 5% / Down 28%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER PRNewswire RSS	Reprice: 22% Fade: 85% Thesis Break: 18% Today: 0.95 - 1.04	Rosen Law Firm Encourages Tigo Energy, Inc. Investors to Inquire About Securities Class Action Investigation - TYGO Parse: PARSED	Repeat class-action solicitation tied to already-known August guidance cut, usually weak incremental price catalyst. Input: ADEQUATE - Recent duplicate lawsuit headline and known underlying event provide enough context to judge low incremental impact.
2026-09-21 22:20:09 Story: 2026-09-21 18:05:24	BOLT ID 6139	DOWN Up 12% / Down 58%	Fish: NO Chart: YES MEDIUM	WATCH_CHART INSIDER ScanScor Filing Bot	Reprice: 41% Fade: 82% Thesis Break: 28% Today: 3.20 - 3.75	BOLT insider purchase filing detected Parse: PARSED	Filing cluster is mostly routine tax-withholding sales and tiny ESPP buys, limiting bullish signal and slightly favoring weak downside interpretation. Input: ADEQUATE - Form 4 excerpts clearly show de minimis purchases versus larger automatic vesting-related sales, enough for event-reaction classification.
2026-09-21 22:11:05 Story: 2026-09-21 18:10:00	CAPR ID 6138	DOWN Up 5% / Down 18%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER PRNewswire RSS	Reprice: 12% Fade: 92% Thesis Break: 88% Today: 8.65 - 9.10	1 WEEK CAPR INVESTOR DEADLINE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Parse: PARSED	Repeat class-action deadline notice adds little new information after the prior FDA/adcom-driven collapse. Input: ADEQUATE - Recent headline history clearly shows this is repetitive legal-solicitation news, not a fresh operational catalyst.
2026-09-21 21:42:44 Story: 2026-09-21 17:40:00	LLY ID 6137	UNCERTAIN Up 18% / Down 10%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER PRNewswire RSS	Reprice: 14% Fade: 72% Thesis Break: 4% Today: 1150.00 - 1178.00	Lilly breaks ground in Houston, one of ten U.S. manufacturing sites announced since 2020 Parse: PARSED	Factory groundbreaking is long-cycle capacity news, not a near-term revenue, regulatory, or clinical catalyst for a mega-cap. Input: ADEQUATE - Headline and context are sufficient to classify this as routine operational news with low immediate repricing impact.
2026-09-21 21:33:40 Story: 2026-09-21 17:30:38	PASG ID 6136	DOWN Up 8% / Down 68%	Fish: YES Chart: YES MEDIUM	STRAY_WILDCAT_DOWN FINANCING ScanScor Filing Bot	Reprice: 54% Fade: 72% Thesis Break: 66% Today: 4.35 - 4.95	PASG SEC filing points to financing activity Parse: PARSED	S-4/A tied to merger and offering language reinforces dilution and shell-risk concerns for a tiny biotech with weak operating fundamentals. Input: ADEQUATE - Filing appears materially relevant, though much excerpted language is boilerplate and should be confirmed against the amended merger terms.
2026-09-21 21:25:09 Story: 2026-09-21 17:21:03	TYRA ID 6135	DOWN Up 12% / Down 68%	Fish: YES Chart: YES MEDIUM	WATCH_CHART FINANCING ScanScor Filing Bot	Reprice: 41% Fade: 72% Thesis Break: 28% Today: 24.40 - 26.20	TYRA SEC filing points to financing activity Parse: PARSED	13G appears tied to the already announced offering, so downside overhang exists but this filing alone may be mostly follow-through noise. Input: ADEQUATE - Recent offering context is sufficient, but the filing itself looks ownership-related rather than a clearly new financing event.
2026-09-21 21:20:08 Story: 2026-09-21 17:07:57	HELP ID 6134	UP Up 62% / Down 24%	Fish: YES Chart: YES MEDIUM	WATCH_CHART INSIDER ScanScor Filing Bot	Reprice: 58% Fade: 67% Thesis Break: 28% Today: 13.10 - 14.25	HELP insider purchase filing detected Parse: PARSED	CEO bought 100,000 shares near market highs, a constructive signal, but repeated recent insider filings reduce novelty and raise fade risk. Input: ADEQUATE - Form 4 details are sufficient, but recent similar insider and financing filings make the standalone signal less clean.
2026-09-21 21:17:46 Story: 2026-09-21 17:15:00	HELP ID 6133	UNCERTAIN Up 8% / Down 6%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER GlobeNewswire RSS	Reprice: 12% Fade: 82% Thesis Break: 4% Today: 13.10 - 13.95	Helus Pharma to Participate at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit Parse: PARSED	Conference participation and fireside chat are routine IR events without new clinical, regulatory, financing, or partnership catalyst. Input: ADEQUATE - Story is clear and recent, but it lacks any concrete catalyst likely to drive durable repricing.
2026-09-21 21:09:42 Story: 2026-09-21 17:08:06	ATR ID 6132	UNCERTAIN Up 18% / Down 22%	Fish: NO Chart: NO MEDIUM	ROUTINE_NEWS REGULATORY ScanScor Filing Bot	Reprice: 24% Fade: 12% Thesis Break: 14% Today: 121.80 - 125.50	ATR files 8-K with regulatory language Parse: PARSED	Rule-matched FDA language appears likely boilerplate in an 8-K, with no confirmed concrete regulatory action disclosed yet. Input: NEED_MORE_FILINGS - Need the actual 8-K item details or exhibit summary to determine whether this is a real catalyst or filing noise.
2026-09-21 21:05:08 Story: 2026-09-21 16:52:51	HELP ID 6131	UNCERTAIN Up 28% / Down 18%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS CLINICAL_DATA ScanScor Filing Bot	Reprice: 24% Fade: 78% Thesis Break: 12% Today: 13.10 - 14.25	HELP files foreign issuer report with market-relevant terms Parse: PARSED	Poster presentations and 12-month analyses are already public conference-style updates, not a new material clinical or regulatory catalyst. Input: ADEQUATE - Filing text and same-day press release align, showing this is largely a repackaged conference update with limited fresh catalyst value.
2026-09-21 21:04:55 Story: 2026-09-21 17:02:46	PODD ID 6130	DOWN Up 12% / Down 58%	Fish: YES Chart: YES LOW	WATCH_CHART FINANCING ScanScor Filing Bot	Reprice: 41% Fade: 63% Thesis Break: 28% Today: 136.00 - 143.00	PODD SEC filing points to financing activity Parse: PARSED	Possible financing or credit amendment language suggests modest downside repricing risk, but filing evidence looks noisy and may be largely boilerplate. Input: NEED_MORE_FILINGS - Need the actual 8-K item details and exhibits to confirm whether this is a new dilutive event or routine debt-document amendment.
2026-09-21 21:02:44 Story: 2026-09-21 17:00:58	TCRT ID 6129	DOWN Up 12% / Down 78%	Fish: YES Chart: YES HIGH	STRAY_WILDCAT_DOWN FINANCING ScanScor Filing Bot	Reprice: 74% Fade: 71% Thesis Break: 83% Today: 1.08 - 1.32	TCRT SEC filing points to financing activity Parse: PARSED	Fresh tiny registered direct offering signals dilution and cash stress for an illiquid microcap, creating immediate downside repricing risk. Input: ADEQUATE - Filing excerpts and recent offering context are sufficient to classify this as actionable financing-driven dilution risk.
2026-09-21 21:02:37 Story: 2026-09-21 17:01:03	WEAV ID 6128	UP Up 58% / Down 12%	Fish: YES Chart: YES MEDIUM	WATCH_CHART REGULATORY ScanScor Filing Bot	Reprice: 46% Fade: 35% Thesis Break: 8% Today: 7.28 - 7.40	WEAV files 8-K with regulatory language Parse: PARSED	HSR early termination de-risks the pending take-private and can tighten merger spread, but most deal value was already known. Input: ADEQUATE - Filing text clearly shows a current merger-closing milestone despite noisy rule tags.
2026-09-21 21:02:31 Story: 2026-09-21 17:02:00	CODX ID 6127	DOWN Up 12% / Down 74%	Fish: YES Chart: YES MEDIUM	STRAY_WILDCAT_DOWN FINANCING ScanScor Filing Bot	Reprice: 71% Fade: 67% Thesis Break: 81% Today: 0.90 - 1.08	CODX SEC filing points to financing activity Parse: PARSED	Proxy seeks approval for warrant-linked share issuance exceeding 20%, signaling likely dilution pressure in a fragile microcap. Input: ADEQUATE - Filing excerpts clearly indicate current warrant exercise approval tied to Nasdaq rules and meaningful potential dilution.
2026-09-21 21:01:31 Story: 2026-09-21 16:59:00	FTK ID 6126	DOWN Up 5% / Down 18%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER PRNewswire RSS	Reprice: 12% Fade: 85% Thesis Break: 20% Today: 29.80 - 31.20	FTK Investors Have Opportunity to Lead Flotek Industries, Inc. Securities Fraud Lawsuit Parse: PARSED	Repeat class-action solicitation is stale legal noise, not a new operational, regulatory, or financing catalyst. Input: ADEQUATE - Recent headline history clearly shows this lawsuit notice has already circulated multiple times.
2026-09-21 20:58:12 Story: 2026-09-21 16:55:28	HSTM ID 6125	UNCERTAIN Up 20% / Down 35%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS FINANCING ScanScor Filing Bot	Reprice: 25% Fade: 80% Thesis Break: 20% Today: 28.40 - 29.60	HSTM SEC filing points to financing activity Parse: PARSED	13D appears to disclose an already announced private placement, so incremental repricing risk now looks limited despite mild dilution overhang. Input: ADEQUATE - Recent company news already disclosed the $40 million placement, reducing novelty and immediate event value of this filing.
2026-09-21 20:49:39 Story: 2026-09-21 16:47:14	VREX ID 6124	DOWN Up 10% / Down 62%	Fish: YES Chart: YES MEDIUM	WATCH_CHART FINANCING ScanScor Filing Bot	Reprice: 38% Fade: 28% Thesis Break: 55% Today: 17.95 - 18.55	VREX SEC filing points to financing activity Parse: PARSED	Proxy filing appears tied to deal/financing mechanics, creating modest downside headline risk but not a clear standalone fundamental catalyst. Input: NEED_MORE_FILINGS - Need the actual merger proxy details and transaction terms, since rule-matched excerpts may reflect boilerplate rather than new dilution.
2026-09-21 20:49:32 Story: 2026-09-21 16:47:49	JAGX ID 6123	DOWN Up 12% / Down 74%	Fish: YES Chart: YES MEDIUM	STRAY_WILDCAT_DOWN COMPLIANCE ScanScor Filing Bot	Reprice: 68% Fade: 88% Thesis Break: 81% Today: 2.20 - 3.10	JAGX files 8-K with regulatory language Parse: PARSED	8-K appears tied to reverse split and Nasdaq compliance, typically bearish for distressed microcaps despite possible brief volatility. Input: ADEQUATE - Need full 8-K text confirmation, but available evidence strongly suggests a compliance-driven reverse-split event.
2026-09-21 20:41:09 Story: 2026-09-21 16:39:00	IRON ID 6122	DOWN Up 3% / Down 12%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER PRNewswire RSS	Reprice: 8% Fade: 92% Thesis Break: 6% Today: 67.50 - 69.20	Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON Parse: PARSED	Repeat plaintiff-law-firm investigation notice tied to an old CRL, with little new information and limited incremental repricing power. Input: ADEQUATE - Recent repeated identical headlines and the underlying February CRL make this low-novelty and low-urgency.
2026-09-21 20:41:05 Story: 2026-09-21 16:39:00	SPRY ID 6121	DOWN Up 3% / Down 12%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER PRNewswire RSS	Reprice: 8% Fade: 95% Thesis Break: 10% Today: 4.20 - 4.45	SPRY Deadline: SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit Parse: PARSED	Repeated class-action reminder is stale legal noise, not a new operational, clinical, or regulatory catalyst. Input: ADEQUATE - Recent headline history clearly shows this lawsuit notice has already circulated multiple times.
2026-09-21 20:39:00 Story: 2026-09-21 16:34:25	PTCT ID 6120	UP Up 68% / Down 22%	Fish: YES Chart: YES MEDIUM	WATCH_CHART REGULATORY ScanScor Filing Bot	Reprice: 61% Fade: 41% Thesis Break: 18% Today: 64.20 - 68.50	PTCT files 8-K with clinical-trial language Parse: PARSED	Completed ST-920 acquisition adds a BLA-stage gene therapy asset with near-term Q4 2026 submission catalyst, but much was previously announced. Input: ADEQUATE - Filing excerpts clearly show acquisition close and near-term BLA timing, enough for event-reaction assessment.
2026-09-21 20:35:08 Story: 2026-09-21 16:23:38	PRTA ID 6119	UP Up 58% / Down 18%	Fish: YES Chart: YES MEDIUM	WATCH_CHART INSIDER ScanScor Filing Bot	Reprice: 46% Fade: 62% Thesis Break: 28% Today: 8.35 - 8.85	PRTA insider purchase filing detected Parse: PARSED	Another sizable 10% owner open-market purchase is constructive, but repeated recent insider buys reduce novelty and raise pop-and-fade risk. Input: ADEQUATE - Filing shows a current 100,000-share purchase by a repeat 10% owner, enough for monitoring despite limited novelty.
2026-09-21 20:33:28 Story: 2026-09-21 16:31:00	AARD ID 6118	DOWN Up 3% / Down 12%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER PRNewswire RSS	Reprice: 8% Fade: 92% Thesis Break: 10% Today: 5.40 - 5.65	AARD Deadline: AARD Investors with Losses in Excess of $100K Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit Parse: PARSED	Another repetitive shareholder lawsuit reminder adds little new information and usually has minimal incremental price impact. Input: ADEQUATE - Recent headline history clearly shows this is repeated legal notice flow, not a fresh operating catalyst.
2026-09-21 20:32:47 Story: 2026-09-21 16:30:00	CVKD ID 6117	UNCERTAIN Up 8% / Down 6%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER GlobeNewswire RSS	Reprice: 10% Fade: 88% Thesis Break: 12% Today: 1.03 - 1.15	Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor Conference Parse: PARSED	Investor conference participation is routine and lacks a new clinical, regulatory, financing, or partnership catalyst. Input: ADEQUATE - News context and company profile are sufficient to classify this as non-actionable routine IR news.
2026-09-21 20:32:27 Story: 2026-09-21 16:30:15	NAMS ID 6116	DOWN Up 18% / Down 72%	Fish: YES Chart: YES MEDIUM	STRAY_WILDCAT_DOWN FINANCING ScanScor Filing Bot	Reprice: 66% Fade: 41% Thesis Break: 24% Today: 21.60 - 23.10	NAMS SEC filing points to financing activity Parse: PARSED	Fresh 8-K financing and warrant signals usually pressure biotech shares through dilution overhang, even if runway improves. Input: NEED_MORE_FILINGS - Need the actual 8-K terms, size, pricing, and counterparties to confirm dilution severity versus routine warrant housekeeping.
2026-09-21 20:32:18 Story: 2026-09-21 16:30:24	BCDA ID 6115	UP Up 58% / Down 18%	Fish: YES Chart: YES MEDIUM	WATCH_CHART COMPLIANCE ScanScor Filing Bot	Reprice: 46% Fade: 72% Thesis Break: 14% Today: 1.04 - 1.22	BCDA files 8-K with regulatory language Parse: PARSED	Regained Nasdaq minimum bid compliance removes a near-term overhang, but this microcap setup still carries high pop-and-fade risk. Input: ADEQUATE - Filing text clearly shows compliance restoration; no substantive FDA catalyst appears in the provided excerpts.
2026-09-21 20:32:07 Story: 2026-09-21 16:30:35	NTHI ID 6114	DOWN Up 28% / Down 67%	Fish: YES Chart: YES MEDIUM	STRAY_WILDCAT_DOWN FINANCING ScanScor Filing Bot	Reprice: 61% Fade: 74% Thesis Break: 31% Today: 3.00 - 3.55	NTHI SEC filing points to financing activity Parse: PARSED	8-K ties to recent financing and capital-structure changes, keeping dilution sensitivity elevated despite preferred redemption removing a worse overhang. Input: ADEQUATE - Filing excerpts and recent related news are sufficient to flag near-term repricing risk, though full 8-K parsing would refine severity.
2026-09-21 20:31:54 Story: 2026-09-21 16:30:41	SNGX ID 6113	DOWN Up 12% / Down 78%	Fish: YES Chart: YES MEDIUM	STRAY_WILDCAT_DOWN FINANCING ScanScor Filing Bot	Reprice: 74% Fade: 71% Thesis Break: 83% Today: 0.33 - 0.40	SNGX SEC filing points to financing activity Parse: PARSED	Microcap ATM expansion signals likely dilution and runway stress, creating immediate downside attention despite possible brief reflex volatility. Input: ADEQUATE - Filing evidence is sufficient to flag dilution risk, though some extracted tags appear boilerplate rather than core catalysts.
2026-09-21 20:31:22 Story: 2026-09-21 16:30:00	RNA ID 6112	UNCERTAIN Up 4% / Down 8%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS INSIDER PRNewswire RSS	Reprice: 10% Fade: 85% Thesis Break: 6% Today: 8.85 - 9.45	Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Parse: PARSED	Inducement grant PR is routine compensation disclosure, recently repeated, and lacks clinical, regulatory, financing, or partnership substance. Input: ADEQUATE - News context and trading setup are sufficient to classify this as non-actionable routine disclosure.
2026-09-21 20:31:17 Story: 2026-09-21 16:30:00	BDX ID 6111	UNCERTAIN Up 8% / Down 6%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER PRNewswire RSS	Reprice: 10% Fade: 85% Thesis Break: 2% Today: 179.00 - 182.50	Arthur Hu to Join BD as Chief Information and Digital Officer Parse: PARSED	Executive CIO appointment is routine leadership news without clinical, regulatory, financial, or commercial catalyst likely to reprice BDX immediately. Input: ADEQUATE - Story and company context are sufficient to judge this as low-urgency routine corporate news.
2026-09-21 20:31:10 Story: 2026-09-21 16:30:00	PTCT ID 6110	UNCERTAIN Up 42% / Down 28%	Fish: NO Chart: YES MEDIUM	WATCH_CHART LICENSING PRNewswire RSS	Reprice: 46% Fade: 58% Thesis Break: 18% Today: 63.90 - 67.80	PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy Parse: PARSED	Deal close was previously announced, but BLA-stage asset transfer and Q4 BLA timing can still cause moderate repricing attention. Input: ADEQUATE - Need exact acquisition economics and whether closing conditions changed versus the August announcement.
2026-09-21 20:30:13 Story: 2026-09-21 16:16:04	HYFT ID 6109	UNCERTAIN Up 8% / Down 10%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS COMPLIANCE ScanScor Filing Bot	Reprice: 14% Fade: 78% Thesis Break: 6% Today: 1.41 - 1.52	HYFT files foreign issuer report with market-relevant terms Parse: PARSED	6-K appears to be routine AGM notice language, not a concrete FDA, Nasdaq, or financing catalyst. Input: ADEQUATE - Filing excerpts indicate meeting logistics only; rule tags likely overcalled materiality.
2026-09-21 20:27:17 Story: 2026-09-21 16:23:41	ANAB ID 6108	UNCERTAIN Up 10% / Down 38%	Fish: NO Chart: NO MEDIUM	ROUTINE_NEWS FINANCING ScanScor Filing Bot	Reprice: 24% Fade: 72% Thesis Break: 18% Today: 53.00 - 56.50	ANAB SEC filing points to financing activity Parse: PARSED	Detected financing language appears historical within a 10-KT, not a clearly new offering or immediate dilution event. Input: ADEQUATE - Need actual offering terms or a dedicated financing filing before treating this as actionable repricing news.
2026-09-21 20:24:21 Story: 2026-09-21 16:21:01	ABVX ID 6107	UNCERTAIN Up 15% / Down 35%	Fish: NO Chart: YES MEDIUM	WATCH_CHART FINANCING ScanScor Filing Bot	Reprice: 30% Fade: 70% Thesis Break: 20% Today: 100.00 - 106.00	ABVX SEC filing points to financing activity Parse: PARSED	F-6EF suggests ADS/ATM registration mechanics, but likely administrative after July financing rather than a clearly new dilutive capital raise. Input: NEED_MORE_FILINGS - Need linked prospectus supplement or ATM sales details to confirm whether this filing creates fresh near-term dilution pressure.
2026-09-21 20:21:50 Story: 2026-09-21 16:16:24	PACS ID 6106	UNCERTAIN Up 10% / Down 28%	Fish: NO Chart: NO MEDIUM	IGNORE FINANCING ScanScor Filing Bot	Reprice: 22% Fade: 65% Thesis Break: 18% Today: 40.90 - 42.80	PACS SEC filing points to financing activity Parse: PARSED	Rule-based filing signal appears misclassified; excerpts indicate executive separation boilerplate, not a clear material financing catalyst. Input: NEED_MORE_FILINGS - Need the actual 8-K item summary or exhibits because provided evidence looks noisy and non-material.
2026-09-21 20:21:43 Story: 2026-09-21 16:17:00	USPH ID 6105	UNCERTAIN Up 12% / Down 18%	Fish: NO Chart: NO MEDIUM	IGNORE REGULATORY ScanScor Filing Bot	Reprice: 22% Fade: 65% Thesis Break: 14% Today: 80.50 - 84.50	USPH files 8-K with regulatory language Parse: PARSED	Rule-matched FDA language in an 8-K appears likely boilerplate, with no clear concrete catalyst or material operational impact disclosed. Input: NEED_MORE_FILINGS - Need the actual 8-K item and exhibit details because the provided excerpt is noisy XBRL text, not confirmed catalyst content.
2026-09-21 20:21:28 Story: 2026-09-21 16:20:00	ANAB ID 6104	UNCERTAIN Up 18% / Down 22%	Fish: NO Chart: NO MEDIUM	ROUTINE_NEWS EARNINGS ScanScor Filing Bot	Reprice: 24% Fade: 72% Thesis Break: 20% Today: 53.50 - 56.80	ANAB files 8-K with clinical-trial language Parse: PARSED	8-K appears tied to routine financial results and recycled partner-trial disclosures, not a clearly new ANAB-specific catalyst. Input: ADEQUATE - Need the actual 8-K item details, but current evidence suggests scanner tag noise rather than a fresh material catalyst.
2026-09-21 20:16:58 Story: 2026-09-21 16:15:00	ANAB ID 6103	UNCERTAIN Up 18% / Down 22%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS EARNINGS GlobeNewswire RSS	Reprice: 24% Fade: 72% Thesis Break: 14% Today: 53.40 - 56.80	Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update Parse: PARSED	Headline signals routine financial results and business update, with no disclosed clinical, regulatory, licensing, or financing catalyst. Input: ADEQUATE - Need full release details to reassess only if guidance, litigation, royalties, or capital allocation materially changed.
2026-09-21 20:14:40 Story: 2026-09-21 16:12:39	ABVX ID 6102	DOWN Up 18% / Down 62%	Fish: YES Chart: YES MEDIUM	WATCH_CHART FINANCING ScanScor Filing Bot	Reprice: 41% Fade: 58% Thesis Break: 22% Today: 99.00 - 106.00	ABVX SEC filing points to financing activity Parse: PARSED	Likely financing-related 6-K suggests dilution overhang, but evidence may partly reflect prior offering disclosures rather than a clearly new capital raise. Input: NEED_MORE_FILINGS - Need the actual 6-K details to confirm whether this is a fresh offering event or recycled historical financing language.
2026-09-21 20:14:09 Story: 2026-09-21 16:13:14	ZCMD ID 6101	DOWN Up 12% / Down 74%	Fish: YES Chart: YES MEDIUM	STRAY_WILDCAT_DOWN FINANCING ScanScor Filing Bot	Reprice: 68% Fade: 86% Thesis Break: 79% Today: 0.70 - 0.86	ZCMD SEC filing points to financing activity Parse: PARSED	Likely dilution-related 6-K on a fragile reverse-split microcap creates immediate downside attention, though any reaction may be noisy and fade-prone. Input: NEED_MORE_FILINGS - Rule-matched excerpts look partly boilerplate, so the exact financing terms need direct filing review.
2026-09-21 20:11:57 Story: 2026-09-21 16:10:24	GTBP ID 6100	DOWN Up 12% / Down 78%	Fish: YES Chart: YES MEDIUM	STRAY_WILDCAT_DOWN FINANCING ScanScor Filing Bot	Reprice: 74% Fade: 67% Thesis Break: 71% Today: 6.10 - 7.60	GTBP SEC filing points to financing activity Parse: PARSED	8-K signals private placement and warrants, a classic microcap dilution overhang likely to pressure shares despite possible runway extension. Input: ADEQUATE - Filing excerpts are sufficient to flag likely dilution, though full pricing terms would improve precision.
2026-09-21 20:11:47 Story: 2026-09-21 16:10:47	TVTX ID 6099	DOWN Up 15% / Down 68%	Fish: YES Chart: YES MEDIUM	STRAY_WILDCAT_DOWN FINANCING ScanScor Filing Bot	Reprice: 61% Fade: 42% Thesis Break: 28% Today: 59.50 - 63.80	TVTX SEC filing points to financing activity Parse: PARSED	Rule-detected 8-K financing/offering signals imply possible dilution, which can pressure a large-cap biotech even if runway improves. Input: NEED_MORE_FILINGS - Need the actual 8-K terms because excerpts look noisy and may include boilerplate rather than confirmed financing details.
2026-09-21 20:11:06 Story: 2026-09-21 16:07:00	CVRX ID 6098	UNCERTAIN Up 8% / Down 12%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER GlobeNewswire RSS	Reprice: 14% Fade: 78% Thesis Break: 10% Today: 2.88 - 3.08	CVRx Appoints John Landry as Chief Financial Officer Parse: PARSED	CFO appointment is routine management news without financing, guidance, strategic transaction, or operating catalyst. Input: ADEQUATE - Headline-only management change is sufficient here because no concrete catalyst or filing-linked financial implication is disclosed.
2026-09-21 20:07:19 Story: 2026-09-21 16:05:37	IMDX ID 6097	UNCERTAIN Up 22% / Down 28%	Fish: NO Chart: YES LOW	WATCH_CHART OTHER ScanScor Filing Bot	Reprice: 31% Fade: 74% Thesis Break: 34% Today: 3.72 - 4.35	IMDX files 8-K with regulatory language Parse: PARSED	8-K appears tied to legacy merger amendment language, with unclear current FDA or compliance impact and limited evidence of a clean catalyst. Input: NEED_MORE_FILINGS - Need the actual 8-K items and exhibits reviewed directly because the scan tags likely include boilerplate and historical merger text.
2026-09-21 20:07:13 Story: 2026-09-21 16:05:47	LNTH ID 6096	UNCERTAIN Up 18% / Down 22%	Fish: NO Chart: NO MEDIUM	ROUTINE_NEWS OTHER ScanScor Filing Bot	Reprice: 28% Fade: 72% Thesis Break: 24% Today: 99.20 - 101.50	LNTH files 8-K with regulatory language Parse: PARSED	8-K appears to mainly update routine merger antitrust timing, not a new approval, financing shock, or deal break. Input: ADEQUATE - Filing excerpts indicate mostly previously disclosed merger process language, limiting immediate catalyst clarity.
2026-09-21 20:07:07 Story: 2026-09-21 16:05:54	PDSB ID 6095	UNCERTAIN Up 34% / Down 28%	Fish: YES Chart: YES MEDIUM	WATCH_CHART OTHER ScanScor Filing Bot	Reprice: 41% Fade: 82% Thesis Break: 24% Today: 0.76 - 0.95	PDSB files 8-K with clinical-trial language Parse: PARSED	8-K appears largely promotional and repeats known pipeline/regulatory language, but this volatile microcap can still react sharply and fade. Input: NEED_MORE_FILINGS - Need the actual 8-K item and exhibits to confirm whether this is a new material event or recycled investor presentation language.
2026-09-21 20:07:06 Story: 2026-09-21 16:05:00	MLYS ID 6094	UNCERTAIN Up 3% / Down 7%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS INSIDER GlobeNewswire RSS	Reprice: 8% Fade: 85% Thesis Break: 2% Today: 27.90 - 28.60	Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Parse: PARSED	Routine inducement equity grant for one employee is immaterial and repeated, with negligible valuation impact. Input: ADEQUATE - News context clearly shows repeated inducement-award releases, supporting low catalyst significance.
2026-09-21 20:07:01 Story: 2026-09-21 16:05:00	ABVX ID 6093	UNCERTAIN Up 22% / Down 28%	Fish: NO Chart: NO MEDIUM	ROUTINE_NEWS EARNINGS GlobeNewswire RSS	Reprice: 24% Fade: 18% Thesis Break: 20% Today: 100.00 - 107.00	Abivax présente les dernières avancées de ses activités et ses résultats financiers du premier semestre 2026 Parse: PARSED	Headline signals routine business update and half-year financials, with no disclosed clinical, regulatory, partnership, or financing catalyst. Input: ADEQUATE - Need the full release details, but current headline alone suggests low-urgency routine earnings-style news.
2026-09-21 20:06:49 Story: 2026-09-21 16:05:00	ABVX ID 6092	UNCERTAIN Up 18% / Down 22%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS EARNINGS GlobeNewswire RSS	Reprice: 24% Fade: 72% Thesis Break: 14% Today: 100.00 - 107.00	Abivax Presents Business Updates and First Half 2026 Financial Results Parse: PARSED	Business update and half-year financials alone lack a fresh concrete catalyst versus recent FDA and financing news. Input: ADEQUATE - Headline-only earnings release with no disclosed surprise catalyst supports low urgency classification.
2026-09-21 20:04:44 Story: 2026-09-21 16:01:00	NYXH ID 6091	UNCERTAIN Up 8% / Down 18%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER GlobeNewswire RSS	Reprice: 16% Fade: 72% Thesis Break: 14% Today: 1.42 - 1.54	Nyxoah Annonce une Transition au Poste de Chief Financial Officer Parse: PARSED	CFO transition alone is usually non-catalytic and lacks financing, guidance, regulatory, or clinical implications. Input: ADEQUATE - Headline and context are sufficient to classify this as routine management-change news with limited immediate repricing relevance.
2026-09-21 20:04:31 Story: 2026-09-21 16:01:00	NYXH ID 6090	DOWN Up 8% / Down 34%	Fish: NO Chart: NO MEDIUM	ROUTINE_NEWS OTHER GlobeNewswire RSS	Reprice: 22% Fade: 18% Thesis Break: 20% Today: 1.40 - 1.52	Nyxoah Announces Chief Financial Officer Transition Parse: PARSED	CFO transition is usually non-catalytic routine management news unless tied to financing, controls, or strategic disruption, which is not indicated here. Input: ADEQUATE - Headline-only management transition limits nuance, but enough context exists to classify this as low-urgency routine news.
2026-09-21 20:04:19 Story: 2026-09-21 16:01:00	XENE ID 6089	UNCERTAIN Up 6% / Down 8%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER GlobeNewswire RSS	Reprice: 10% Fade: 85% Thesis Break: 78% Today: 38.20 - 39.80	Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit Parse: PARSED	Investor conference presentation notice is routine and lacks new clinical, regulatory, financing, or partnership substance. Input: ADEQUATE - Fresh headline is clear and recent context already explains the major repricing catalyst.
2026-09-21 20:02:46 Story: 2026-09-21 16:01:07	WW ID 6088	UNCERTAIN Up 18% / Down 22%	Fish: NO Chart: NO MEDIUM	ROUTINE_NEWS OTHER ScanScor Filing Bot	Reprice: 24% Fade: 78% Thesis Break: 20% Today: 15.70 - 17.20	WW files 8-K with regulatory language Parse: PARSED	Rule-matched 8-K/A appears dominated by boilerplate and amendment language, with no clear fresh catalyst confirmed from the provided excerpts. Input: NEED_MORE_FILINGS - Need the actual amended 8-K item details; current FDA and Nasdaq tags look likely boilerplate or false-positive term matches.
2026-09-21 20:02:37 Story: 2026-09-21 16:01:07	SGMO ID 6087	DOWN Up 8% / Down 86%	Fish: YES Chart: YES HIGH	STRAY_WILDCAT_DOWN COMPLIANCE ScanScor Filing Bot	Reprice: 78% Fade: 22% Thesis Break: 97% Today: -	SGMO files 8-K with regulatory language Parse: PARSED	8-K confirms Chapter 11 asset sale completion and Nasdaq delisting effectiveness, reinforcing severe equity impairment risk. Input: ADEQUATE - Filing excerpts clearly show bankruptcy, completed asset disposition, and pending delisting, enough for immediate event-reaction assessment.
2026-09-21 19:55:11 Story: 2026-09-21 15:54:00	PRCT ID 6086	UNCERTAIN Up 3% / Down 12%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER PRNewswire RSS	Reprice: 8% Fade: 92% Thesis Break: 18% Today: 18.20 - 18.80	PRCT Deadline: PRCT Investors with Losses in Excess of $100K Have Opportunity to Lead PROCEPT BioRobotics Corporation Securities Fraud Lawsuit Parse: PARSED	Repeated class-action deadline reminder is stale legal solicitation, not a new operational, regulatory, or financing catalyst. Input: ADEQUATE - Recent headline history clearly shows this lawsuit notice is repetitive and unlikely to drive fresh repricing.
2026-09-21 19:30:21 Story: 2026-09-21 15:29:11	SPRU ID 6085	UNCERTAIN Up 18% / Down 22%	Fish: NO Chart: NO MEDIUM	IGNORE REGULATORY ScanScor Filing Bot	Reprice: 24% Fade: 82% Thesis Break: 14% Today: 1.98 - 2.22	SPRU files 8-K with regulatory language Parse: PARSED	Rule-matched 8-K/A appears boilerplate and non-biotech; no clear material catalyst is visible from the filing summary. Input: NEED_MORE_FILINGS - Need the actual amended 8-K event details because the FDA tag likely reflects false-positive boilerplate text.
2026-09-21 19:24:33 Story: 2026-09-21 15:23:00	SPRY ID 6084	UNCERTAIN Up 5% / Down 18%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER PRNewswire RSS	Reprice: 12% Fade: 92% Thesis Break: 10% Today: 4.20 - 4.45	SPRY Stockholders with Large Losses Should Contact Robbins LLP About Leading the ARS Pharmaceuticals Inc. Class Action Before the October 5, 2026 Deadline Parse: PARSED	Repeated shareholder lawsuit reminder adds little new information and usually does not create fresh biotech repricing. Input: ADEQUATE - Recent headline history clearly shows this is repetitive legal solicitation, not a new operating or regulatory catalyst.
2026-09-21 19:14:50 Story: 2026-09-21 15:13:00	ARDX ID 6083	DOWN Up 3% / Down 12%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER PRNewswire RSS	Reprice: 8% Fade: 92% Thesis Break: 18% Today: 3.40 - 3.52	ARDX Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Ardelyx, Inc. Parse: PARSED	Law-firm class action reminder is recycled post-drop litigation noise, not a fresh operational, regulatory, or financing catalyst. Input: ADEQUATE - Recent context clearly shows multiple similar lawsuit notices, making this low-novelty and unlikely to drive meaningful new repricing.
2026-09-21 18:26:33 Story: 2026-09-21 14:24:00	ENSG ID 6082	DOWN Up 3% / Down 18%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER PRNewswire RSS	Reprice: 10% Fade: 92% Thesis Break: 12% Today: 171.50 - 175.50	Rosen Law Firm Encourages The Ensign Group, Inc. Investors to Inquire About Securities Class Action Investigation - ENSG Parse: PARSED	Repeat plaintiff-lawyer investigation notice tied to old short-report allegations, with no new filing, facts, regulator action, or company update. Input: ADEQUATE - News context clearly shows this is repetitive legal-solicitation noise rather than a fresh catalyst.
2026-09-21 17:30:09 Story: 2026-09-21 13:15:59	RDY ID 6081	UNCERTAIN Up 18% / Down 22%	Fish: NO Chart: NO MEDIUM	ROUTINE_NEWS REGULATORY ScanScor Filing Bot	Reprice: 24% Fade: 72% Thesis Break: 20% Today: 12.20 - 12.60	RDY files foreign issuer report with market-relevant terms Parse: PARSED	Rule-tagged 6-K lacks disclosed material details and resembles repeated foreign issuer filing noise, limiting immediate repricing odds. Input: NEED_MORE_FILINGS - Need the actual 6-K contents or exhibits to determine whether any FDA-related language reflects a current material event.
2026-09-21 17:12:24 Story: 2026-09-21 13:11:00	COO ID 6080	DOWN Up 8% / Down 22%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER PRNewswire RSS	Reprice: 18% Fade: 85% Thesis Break: 12% Today: 53.80 - 56.20	Rosen Law Firm Encourages The Cooper Companies, Inc. Investors to Inquire About Securities Class Action Investigation - COO Parse: PARSED	Law-firm investigation notice is derivative of the prior earnings-driven drop and rarely creates fresh standalone repricing in a large-cap name. Input: ADEQUATE - Enough context shows this is repetitive legal-advertising noise after already digested bad guidance and strategic disappointment.
2026-09-21 16:28:24 Story: 2026-09-21 12:27:00	BBNX ID 6079	UNCERTAIN Up 8% / Down 18%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER PRNewswire RSS	Reprice: 12% Fade: 92% Thesis Break: 28% Today: 21.10 - 22.30	Beta Bionics (NASDAQ: BBNX) Faces Securities Class Action Amid iLet FDA Compliance -- HBSS Parse: PARSED	Law-firm class action notice repeats known FDA compliance issues and usually adds little new price-moving information. Input: ADEQUATE - Recent headline history shows this lawsuit alert is repetitive, reducing immediate catalyst value.
2026-09-21 16:26:20 Story: 2026-09-21 12:25:00	HIMS ID 6078	DOWN Up 8% / Down 22%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER PRNewswire RSS	Reprice: 12% Fade: 88% Thesis Break: 68% Today: 27.80 - 29.60	Hims & Hers Health (HIMS) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before November 2, 2026 Lead Plaintiff Deadline Parse: PARSED	Class-action filing is derivative of already-known FTC allegations and similar lawsuit alerts, so incremental repricing impact is likely limited. Input: ADEQUATE - Recent headline history clearly shows this is repetitive legal-advertising news rather than a fresh underlying catalyst.
2026-09-21 16:26:01 Story: 2026-09-21 12:23:00	VEEV ID 6077	UNCERTAIN Up 18% / Down 12%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER PRNewswire RSS	Reprice: 20% Fade: 72% Thesis Break: 8% Today: 255.00 - 264.00	Veeva lance le Falcon Router pour le triage agentique de tous les canaux de reporting Parse: PARSED	Product launch PR without disclosed revenue impact, customer win, or regulatory catalyst; likely incremental and already echoed in multiple language releases. Input: ADEQUATE - Story is clear and recent, but lacks financial magnitude or adoption details needed for stronger event-repricing conviction.
2026-09-21 16:22:17 Story: 2026-09-21 12:21:00	AARD ID 6076	DOWN Up 3% / Down 18%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER PRNewswire RSS	Reprice: 12% Fade: 92% Thesis Break: 88% Today: 5.10 - 5.45	AARD Investor Notice: Hagens Berman Alerts Investors in Aardvark Therapeutics (NASDAQ: AARD) to Filing of Securities Fraud Class Action Parse: PARSED	Repeat class-action alert on already disclosed clinical-hold issues; incremental price impact is likely limited and low-quality. Input: ADEQUATE - Recent headline history clearly shows this lawsuit notice is repetitive rather than a fresh catalyst.
2026-09-21 16:14:20 Story: 2026-09-21 12:13:00	CAPR ID 6075	DOWN Up 3% / Down 18%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER PRNewswire RSS	Reprice: 8% Fade: 92% Thesis Break: 86% Today: 8.75 - 9.20	CAPR 1-WEEK DEADLINE ALERT: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28 Deadline Parse: PARSED	Repeat class-action deadline alert adds little new information after prior FDA-driven collapse and multiple similar lawsuit notices. Input: ADEQUATE - Story is repetitive legal solicitation, not a fresh operational, regulatory, or financing catalyst.
2026-09-21 16:12:30 Story: 2026-09-21 12:10:00	PRCT ID 6074	DOWN Up 5% / Down 18%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER PRNewswire RSS	Reprice: 12% Fade: 85% Thesis Break: 8% Today: 18.20 - 19.10	PRCT FINAL DEADLINE ALERT: PROCEPT BioRobotics Corporation Investors Alerted to September 22, 2026 Lead Plaintiff Deadline in Securities Fraud Class Action Lawsuit Parse: PARSED	Lead-plaintiff lawsuit reminder is repetitive, backward-looking, and usually non-catalytic after the core allegations were already absorbed. Input: ADEQUATE - Recent headline history clearly shows repeated lawsuit notices, reducing odds this specific alert drives fresh repricing.
2026-09-21 16:02:12 Story: 2026-09-21 12:00:00	CGEM ID 6073	UNCERTAIN Up 6% / Down 8%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER GlobeNewswire RSS	Reprice: 10% Fade: 85% Thesis Break: 4% Today: 20.60 - 21.40	Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum Parse: PARSED	Conference participation without new data, guidance, deal, or regulatory catalyst is routine and unlikely to drive meaningful repricing. Input: ADEQUATE - Story is clear and recent context confirms no new catalyst beyond an investor-facing forum appearance.
2026-09-21 15:25:09 Story: 2026-09-21 11:11:33	NVO ID 6072	UNCERTAIN Up 10% / Down 20%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER ScanScor Filing Bot	Reprice: 18% Fade: 85% Thesis Break: 15% Today: 38.90 - 40.80	NVO files foreign issuer report with market-relevant terms Parse: PARSED	Detected 6-K appears to be routine buyback/listing disclosure, not a clear new material catalyst beyond already moving sentiment. Input: ADEQUATE - Need the full 6-K text to confirm no hidden regulatory update, but provided excerpt looks non-material.
2026-09-21 15:13:01 Story: 2026-09-21 11:12:00	ARDX ID 6071	DOWN Up 5% / Down 18%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER PRNewswire RSS	Reprice: 12% Fade: 85% Thesis Break: 10% Today: 3.34 - 3.48	ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit Parse: PARSED	Law-firm class action notice is derivative, already telegraphed, and rarely creates fresh standalone repricing in a liquid mid-cap biotech. Input: ADEQUATE - Recent similar lawsuit headlines and the underlying August commercial miss are already in context, making this notice low incremental value.
2026-09-21 14:35:43 Story: 2026-09-21 10:33:00	JNJ ID 6070	UP Up 58% / Down 12%	Fish: NO Chart: YES MEDIUM	WATCH_CHART REGULATORY GlobeNewswire RSS	Reprice: 34% Fade: 42% Thesis Break: 8% Today: 268.00 - 274.00	European Commission approval of ICOTYDE™▼(icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide Parse: PARSED	EC approval is a real regulatory catalyst, but JNJ’s size makes immediate stock repricing likely modest rather than explosive. Input: ADEQUATE - Fresh approval headline and company scale are sufficient to judge this as watchlist-worthy but not a high-urgency fish alarm.
2026-09-21 14:02:54 Story: 2026-09-21 10:00:00	SNN ID 6069	UNCERTAIN Up 8% / Down 6%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER GlobeNewswire RSS	Reprice: 10% Fade: 72% Thesis Break: 4% Today: 27.30 - 27.85	Smith+Nephew to showcase leading shoulder technologies for joint repair and reconstruction at ICSES 2026 Parse: PARSED	Conference showcase language is routine marketing without new data, approvals, partnerships, or financial impact likely to reprice SNN immediately. Input: ADEQUATE - Headline and context are sufficient to classify this as non-actionable routine conference publicity.
2026-09-21 14:00:10 Story: 2026-09-21 09:48:51	HYFT ID 6068	UNCERTAIN Up 38% / Down 22%	Fish: NO Chart: YES MEDIUM	WATCH_CHART PARTNERSHIP ScanScor Filing Bot	Reprice: 41% Fade: 78% Thesis Break: 18% Today: 1.33 - 1.58	HYFT files foreign issuer report with market-relevant terms Parse: PARSED	6-K appears to package a performance-validation deployment with AMD/Vultr, but lacks clear financing, FDA, or binding commercial catalyst. Input: ADEQUATE - Need full 6-K review to confirm whether this is merely promotional validation or includes material commercial terms.
2026-09-21 13:16:55 Story: 2026-09-21 09:15:00	QTTB ID 6067	UP Up 58% / Down 18%	Fish: YES Chart: YES MEDIUM	WATCH_CHART CLINICAL_DATA PRNewswire RSS	Reprice: 61% Fade: 72% Thesis Break: 28% Today: 10.20 - 11.60	Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026 Parse: PARSED	Late-breaking trial presentation signals potentially supportive durability data, but this is still a conference-preview headline without the actual dataset. Input: ADEQUATE - Enough context exists to flag event-driven attention, though actual abstract details would improve conviction on magnitude and durability.
2026-09-21 13:16:19 Story: 2026-09-21 09:12:01	NSPR ID 6066	DOWN Up 22% / Down 71%	Fish: YES Chart: YES MEDIUM	STRAY_WILDCAT_DOWN FINANCING ScanScor Filing Bot	Reprice: 74% Fade: 68% Thesis Break: 41% Today: 0.68 - 0.84	NSPR SEC filing points to financing activity Parse: PARSED	Warrant amendments signal potential dilution and financing overhang, despite runway support tied to anticipated FDA approval. Input: ADEQUATE - Filing excerpts and matching press release provide enough detail to assess near-term dilution-driven reaction risk.
2026-09-21 13:16:13 Story: 2026-09-21 09:15:34	AVR ID 6065	DOWN Up 12% / Down 68%	Fish: YES Chart: YES MEDIUM	STRAY_WILDCAT_DOWN FINANCING ScanScor Filing Bot	Reprice: 61% Fade: 41% Thesis Break: 34% Today: 7.75 - 8.35	AVR SEC filing points to financing activity Parse: PARSED	424B3 prospectus supplement tied to registered selling stockholder shares signals likely dilution or overhang, creating near-term downside repricing risk. Input: ADEQUATE - Enough filing detail exists to classify this as financing-related overhang, though exact incremental dilution mechanics are not fully visible here.
2026-09-21 13:07:07 Story: 2026-09-21 09:05:27	RXRX ID 6064	UP Up 62% / Down 24%	Fish: YES Chart: YES MEDIUM	WATCH_CHART LICENSING ScanScor Filing Bot	Reprice: 68% Fade: 58% Thesis Break: 18% Today: 3.72 - 4.25	RXRX files 8-K with regulatory language Parse: PARSED	8-K appears to disclose a real Tempus licensing deal, which can reprice sentiment, but terms look incremental rather than thesis-changing. Input: ADEQUATE - Key filing excerpts show a current material agreement, while FDA and Nasdaq tags appear partly boilerplate and less decision-relevant.
2026-09-21 13:04:47 Story: 2026-09-21 09:00:00	PALI ID 6063	UNCERTAIN Up 8% / Down 6%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER GlobeNewswire RSS	Reprice: 10% Fade: 85% Thesis Break: 4% Today: 1.56 - 1.70	Palisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation Forum Parse: PARSED	Conference presentation notice is routine, non-catalytic news with little standalone repricing power absent new data or financing details. Input: ADEQUATE - Headline and context are sufficient to classify this as routine investor-conference news without actionable catalyst content.
2026-09-21 13:02:40 Story: 2026-09-21 09:00:00	NAMS ID 6062	UP Up 82% / Down 18%	Fish: YES Chart: YES HIGH	STRAY_WILDCAT_UP REGULATORY GlobeNewswire RSS	Reprice: 86% Fade: 38% Thesis Break: 9% Today: 22.60 - 25.80	NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination) Parse: PARSED	European Commission approval is a concrete commercialization catalyst, though some benefit was pre-signaled by prior positive CHMP opinion. Input: ADEQUATE - Key context is sufficient, including prior CHMP news, valuation, short interest, and recent price weakness.
2026-09-21 13:02:26 Story: 2026-09-21 09:00:00	AVLN ID 6061	UP Up 68% / Down 22%	Fish: YES Chart: YES MEDIUM	WATCH_CHART CLINICAL_DATA GlobeNewswire RSS	Reprice: 61% Fade: 41% Thesis Break: 18% Today: 30.60 - 34.80	Avalyn Publishes Phase 1 Data Highlighting AP02’s Lung-Targeted Delivery and Encouraging Safety Profile Parse: PARSED	Fresh Phase 1 human data with lung-targeted exposure and tolerability can support near-term upside attention, though publication-style framing limits shock value. Input: ADEQUATE - Need exact efficacy and comparator details to judge whether this is materially new versus recent conference disclosures.
2026-09-21 13:02:13 Story: 2026-09-21 09:00:00	NSPR ID 6060	DOWN Up 22% / Down 68%	Fish: YES Chart: YES MEDIUM	STRAY_WILDCAT_DOWN FINANCING GlobeNewswire RSS	Reprice: 61% Fade: 74% Thesis Break: 58% Today: 0.70 - 0.84	InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million Parse: PARSED	Warrant amendments signal contingent dilution and cash need, with only indirect FDA timing support, creating likely pressure despite possible speculative approval-linked interest. Input: ADEQUATE - Headline and company context are sufficient to assess near-term financing-driven repricing risk.
2026-09-21 12:56:26 Story: 2026-09-21 08:55:40	TLX ID 6059	DOWN Up 22% / Down 74%	Fish: YES Chart: YES MEDIUM	STRAY_WILDCAT_DOWN FINANCING ScanScor Filing Bot	Reprice: 79% Fade: 41% Thesis Break: 36% Today: 10.75 - 12.05	TLX SEC filing points to financing activity Parse: PARSED	6-K appears tied to acquisition financing and possible share issuance, creating near-term dilution overhang despite strategic rationale. Input: ADEQUATE - Filing signal is noisy, but acquisition financing language and current price weakness make immediate downside monitoring warranted.
2026-09-21 12:47:31 Story: 2026-09-21 08:37:00	GOVX ID 6058	UP Up 58% / Down 24%	Fish: YES Chart: YES MEDIUM	STRAY_WILDCAT_UP PRECLINICAL NewMediaWire RSS	Reprice: 63% Fade: 88% Thesis Break: 79% Today: 0.34 - 0.52	GeoVax Next-Generation MVA Vaccine Demonstrates Durable Single-Dose Protection in Preclinical Models Parse: PARSED	Preclinical single-dose mpox protection can spark a microcap bounce, but bioRxiv animal data and severe dilution history make fades likely. Input: ADEQUATE - News, market cap, price collapse, and recent financing/compliance context are sufficient for an event-reaction judgment.
2026-09-21 12:47:05 Story: 2026-09-21 08:45:00	ANIX ID 6057	UNCERTAIN Up 38% / Down 18%	Fish: NO Chart: YES MEDIUM	WATCH_CHART REGULATORY PRNewswire RSS	Reprice: 34% Fade: 82% Thesis Break: 12% Today: 2.74 - 3.15	Anixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040 Parse: PARSED	Issued Australian patent modestly strengthens IP, but this is non-revenue, non-clinical, partly telegraphed news with likely pop-and-fade behavior. Input: ADEQUATE - Recent similar patent acceptance and Korean patent news reduce novelty, making immediate repricing potential limited despite small-cap sensitivity.
2026-09-21 12:37:30 Story: 2026-09-21 08:35:27	PETS ID 6056	UNCERTAIN Up 18% / Down 22%	Fish: NO Chart: NO MEDIUM	ROUTINE_NEWS OTHER ScanScor Filing Bot	Reprice: 24% Fade: 72% Thesis Break: 28% Today: 1.58 - 1.82	PETS files 8-K with regulatory language Parse: PARSED	Detected tags appear driven by boilerplate and director appointment language, not a clear new regulatory, financing, or transaction catalyst. Input: NEED_MORE_FILINGS - Need the actual 8-K item details because the excerpts shown are noisy and likely misclassified by keyword matching.
2026-09-21 12:33:18 Story: 2026-09-21 08:30:00	PETS ID 6055	UNCERTAIN Up 8% / Down 6%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER GlobeNewswire RSS	Reprice: 12% Fade: 78% Thesis Break: 10% Today: 1.62 - 1.76	PetMeds Enhances Board of Directors with Appointment of Tamar Elkeles as New Independent Director Parse: PARSED	Independent director appointment is routine governance news without concrete financial, regulatory, or operating catalyst for immediate repricing. Input: ADEQUATE - News and company context are sufficient; no actionable catalyst is disclosed beyond board refresh.
2026-09-21 12:26:16 Story: 2026-09-21 08:24:00	VEEV ID 6054	UNCERTAIN Up 24% / Down 14%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER PRNewswire RSS	Reprice: 18% Fade: 72% Thesis Break: 8% Today: 255.00 - 264.00	Veeva stellt den „Falcon Router" für die agentenbasierte Triage aller Meldekanäle vor Parse: PARSED	Product launch PR for an early-adopter AI workflow tool lacks revenue, customer, or regulatory catalyst and is unlikely to drive meaningful immediate repricing. Input: ADEQUATE - Story, company scale, and recent duplicate releases are sufficient to judge this as low-urgency routine product news.
2026-09-21 12:04:21 Story: 2026-09-21 08:00:00	NTHI ID 6053	UNCERTAIN Up 24% / Down 18%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER GlobeNewswire RSS	Reprice: 22% Fade: 86% Thesis Break: 20% Today: 3.05 - 3.75	NeOnc Charting New Nasal Route to Treating Brain Cancer Parse: PARSED	Promotional article language without new clinical, regulatory, financing, or partnership substance makes immediate repricing unlikely. Input: ADEQUATE - Headline and body lack concrete catalyst details, but recent context is sufficient to classify this as routine promotional news.
2026-09-21 12:04:08 Story: 2026-09-21 08:00:00	IMMP ID 6052	DOWN Up 8% / Down 42%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS COMPLIANCE GlobeNewswire RSS	Reprice: 38% Fade: 72% Thesis Break: 28% Today: 0.26 - 0.31	Change to American Depositary Share Ratio Parse: PARSED	ADS ratio changes are usually cosmetic and often tied to listing maintenance, with limited standalone upside and mild negative signaling. Input: ADEQUATE - Headline and market context are sufficient because ADS ratio changes rarely create durable catalyst-driven repricing alone.
2026-09-21 12:02:56 Story: 2026-09-21 08:00:17	CUE ID 6051	UNCERTAIN Up 58% / Down 42%	Fish: YES Chart: YES MEDIUM	WATCH_CHART CLINICAL_DATA ScanScor Filing Bot	Reprice: 71% Fade: 82% Thesis Break: 28% Today: 41.00 - 52.00	CUE files 8-K with clinical-trial language Parse: PARSED	Likely 8-K formalizes already announced positive Phase 2 topline data, so attention is warranted but novelty appears limited and fade risk is high. Input: ADEQUATE - Recent press release context makes this interpretable, but the filing text appears noisy and may mix boilerplate with current-event language.
2026-09-21 12:02:27 Story: 2026-09-21 08:00:00	JNJ ID 6050	UP Up 68% / Down 12%	Fish: YES Chart: YES MEDIUM	WATCH_CHART CLINICAL_DATA PRNewswire RSS	Reprice: 54% Fade: 42% Thesis Break: 18% Today: 267.00 - 275.00	CAPLYTA® (lumateperone) shows significant and rapid improvement in bipolar mania in pivotal Phase 3 study Parse: PARSED	Positive pivotal Phase 3 mania data expands CAPLYTA’s label opportunity, but JNJ’s huge market cap limits immediate percentage repricing. Input: ADEQUATE - Topline efficacy, safety, market cap, and price context are sufficient for an event-reaction judgment.
2026-09-21 11:35:20 Story: 2026-09-21 07:30:00	IFRX ID 6049	UNCERTAIN Up 8% / Down 14%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER GlobeNewswire RSS	Reprice: 12% Fade: 78% Thesis Break: 22% Today: 2.00 - 2.16	InflaRx to Host Virtual Capital Markets Day Parse: PARSED	Capital markets day scheduling is routine IR news and lacks new clinical, regulatory, financing, or partnership substance. Input: ADEQUATE - News context and trading history are sufficient to classify this as low-urgency routine event news.
2026-09-21 11:35:14 Story: 2026-09-21 07:30:00	MDCX ID 6048	DOWN Up 22% / Down 61%	Fish: YES Chart: YES MEDIUM	STRAY_WILDCAT_DOWN OTHER GlobeNewswire RSS	Reprice: 58% Fade: 74% Thesis Break: 67% Today: 0.14 - 0.20	Medicus Pharma Announces Exclusive Development Focus for SkinJect® in Gorlin Syndrome Following Commercial, Clinical and Regulatory Assessment Parse: PARSED	Narrowing focus while ending nBCC development reads as pipeline contraction, not a new catalyst, despite capital-efficiency framing and existing FDA-authorized Gorlin study. Input: ADEQUATE - Fresh headline is clear enough: strategic refocus and program termination matter more than prior positive Phase 2 context for immediate reaction.
2026-09-21 11:33:28 Story: 2026-09-21 07:30:00	HELP ID 6047	UNCERTAIN Up 28% / Down 12%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS CLINICAL_DATA GlobeNewswire RSS	Reprice: 24% Fade: 72% Thesis Break: 8% Today: 12.10 - 13.35	Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026 Parse: PARSED	Conference poster analyses without clearly new topline human efficacy results usually produce limited repricing and any pop is prone to fade. Input: ADEQUATE - Need explicit novelty versus prior HLP003 data to justify higher urgency.
2026-09-21 11:15:16 Story: 2026-09-21 07:00:14	TLSA ID 6046	UP Up 68% / Down 18%	Fish: YES Chart: YES MEDIUM	WATCH_CHART OTHER ScanScor Filing Bot	Reprice: 72% Fade: 74% Thesis Break: 29% Today: 0.87 - 1.08	TLSA files foreign issuer report with market-relevant terms Parse: PARSED	Last-patient-last-visit and October topline timing can spark speculative biotech interest, but this is a setup milestone, not efficacy data. Input: ADEQUATE - Filing text clearly identifies a current clinical milestone and near-term topline catalyst, sufficient for event-reaction assessment.
2026-09-21 11:15:12 Story: 2026-09-21 07:00:14	SCNI ID 6045	UP Up 68% / Down 32%	Fish: YES Chart: YES MEDIUM	STRAY_WILDCAT_UP COMPLIANCE ScanScor Filing Bot	Reprice: 74% Fade: 88% Thesis Break: 79% Today: 1.48 - 2.15	SCNI files foreign issuer report with market-relevant terms Parse: PARSED	Regaining Nasdaq bid-price compliance removes a near-term delisting overhang, but SCNI remains an extremely fragile microcap prone to pop-and-fade action. Input: ADEQUATE - The filing clearly states regained Nasdaq compliance, which is actionable despite noisy tag extraction and weak company quality.
2026-09-21 11:15:07 Story: 2026-09-21 07:04:32	AZN ID 6044	UNCERTAIN Up 38% / Down 22%	Fish: NO Chart: NO MEDIUM	ROUTINE_NEWS REGULATORY ScanScor Filing Bot	Reprice: 31% Fade: 72% Thesis Break: 12% Today: 164.00 - 169.00	AZN files foreign issuer report with market-relevant terms Parse: PARSED	Likely a 6-K packaging already-known positive CHMP and phase 3 details, material but not clearly fresh enough for immediate repricing. Input: NEED_MORE_FILINGS - Need the full 6-K and prior press-release timing to confirm whether this filing contains genuinely new regulatory information.
2026-09-21 11:14:41 Story: 2026-09-21 07:14:05	AVTR ID 6043	UNCERTAIN Up 12% / Down 18%	Fish: NO Chart: NO HIGH	IGNORE OTHER ScanScor Filing Bot	Reprice: 14% Fade: 78% Thesis Break: 10% Today: 15.10 - 15.85	AVTR files 8-K with clinical-trial language Parse: PARSED	Detected clinical-trial and FDA terms appear boilerplate in an employment-related 8-K, not a concrete catalyst likely to reprice shares. Input: ADEQUATE - Enough evidence suggests term-match noise; full 8-K review could confirm, but current excerpts do not show actionable clinical or regulatory news.

Instant Intelligence for Biotech Investors

ScanScor WCFF Events